BGJ398 (Novartis) is an additional potent, pan-FGFR inhibitor currently undergoing Phase I/II clinical trials after initially demonstrating antitumor activity in RT112 bladder cancer xenografts models overexpressing wild-type FGFR3 [91]. Here, FGFR3 is linked to urinary bladder cancer.